Evercore ISI upgraded shares of Bausch Health Companies (TSE:BHC – Free Report) to a hold rating in a research note published ...

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Bausch Health Companies Inc. ( NYSE:BHC ) shareholders should be happy to see the share price up 26% in the last ...

Bausch Health Companies Inc. is a global pharmaceutical company with a long history dating back to 1853. The company's portfolio spans a wide range of products, including eye care, pharmaceuticals ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Health-care companies rose slightly amid mixed earnings. CVS Health replaced its top executive as it warned that its coming earnings will once again fall short of Wall Street expectations, sending ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Revenue: $1.19 billion for Bausch Health excluding B+L, up 5% reported and 6% organic year-over-year. Adjusted EBITDA: $614 million for Bausch Health excluding B+L, an 8% increase from the prior year.

In a report released today, Umer Raffat from Evercore ISI maintained a Hold rating on Bausch Health Companies (BHC – Research Report).

We recently compiled a list of the Carl Icahn Stock Portfolio: 7 Best Stocks to Buy. In this article, we are going to take a ...

Short interest in Bausch Health Companies Inc (NYSE:BHC) decreased during the last reporting period, falling from 18.60M to 14.78M. This put 4.36% of the company's publicly available shares short.